Literature DB >> 16131611

p53 isoforms can regulate p53 transcriptional activity.

Jean-Christophe Bourdon1, Kenneth Fernandes, Fiona Murray-Zmijewski, Geng Liu, Alexandra Diot, Dimitris P Xirodimas, Mark K Saville, David P Lane.   

Abstract

The recently discovered p53-related genes, p73 and p63, express multiple splice variants and N-terminally truncated forms initiated from an alternative promoter in intron 3. To date, no alternative promoter and multiple splice variants have been described for the p53 gene. In this study, we show that p53 has a gene structure similar to the p73 and p63 genes. The human p53 gene contains an alternative promoter and transcribes multiple splice variants. We show that p53 variants are expressed in normal human tissue in a tissue-dependent manner. We determine that the alternative promoter is conserved through evolution from Drosophila to man, suggesting that the p53 family gene structure plays an essential role in the multiple activities of the p53 family members. Consistent with this hypothesis, p53 variants are differentially expressed in human breast tumors compared with normal breast tissue. We establish that p53beta can bind differentially to promoters and can enhance p53 target gene expression in a promoter-dependent manner, while Delta133p53 is dominant-negative toward full-length p53, inhibiting p53-mediated apoptosis. The differential expression of the p53 isoforms in human tumors may explain the difficulties in linking p53 status to the biological properties and drug sensitivity of human cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16131611      PMCID: PMC1221884          DOI: 10.1101/gad.1339905

Source DB:  PubMed          Journal:  Genes Dev        ISSN: 0890-9369            Impact factor:   11.361


  40 in total

1.  Biological significance of a small highly conserved region in the N terminus of the p53 tumour suppressor protein.

Authors:  W L Liu; C Midgley; C Stephen; M Saville; D P Lane
Journal:  J Mol Biol       Date:  2001-11-02       Impact factor: 5.469

2.  Definition of the p53 functional domains necessary for inducing apoptosis.

Authors:  J Zhu; S Zhang; J Jiang; X Chen
Journal:  J Biol Chem       Date:  2000-12-22       Impact factor: 5.157

3.  Conformational changes in p53 analysed using new antibodies to the core DNA binding domain of the protein.

Authors:  B Vojtesek; H Dolezalova; L Lauerova; M Svitakova; P Havlis; J Kovarik; C A Midgley; D P Lane
Journal:  Oncogene       Date:  1995-01-19       Impact factor: 9.867

4.  Isolation of a full-length mouse cDNA clone coding for an immunologically distinct p53 molecule.

Authors:  D Wolf; N Harris; N Goldfinger; V Rotter
Journal:  Mol Cell Biol       Date:  1985-01       Impact factor: 4.272

5.  Characterization of the human p53 gene.

Authors:  P Lamb; L Crawford
Journal:  Mol Cell Biol       Date:  1986-05       Impact factor: 4.272

6.  p53 mutant mice that display early ageing-associated phenotypes.

Authors:  Stuart D Tyner; Sundaresan Venkatachalam; Jene Choi; Stephen Jones; Nader Ghebranious; Herbert Igelmann; Xiongbin Lu; Gabrielle Soron; Benjamin Cooper; Cory Brayton; Sang Hee Park; Timothy Thompson; Gerard Karsenty; Allan Bradley; Lawrence A Donehower
Journal:  Nature       Date:  2002-01-03       Impact factor: 49.962

7.  p63alpha and DeltaNp63alpha can induce cell cycle arrest and apoptosis and differentially regulate p53 target genes.

Authors:  M Dohn; S Zhang; X Chen
Journal:  Oncogene       Date:  2001-05-31       Impact factor: 9.867

8.  Direct transactivation of c-Ha-Ras gene by p53: evidence for its involvement in p53 transactivation activity and p53-mediated apoptosis.

Authors:  V Deguin-Chambon; M Vacher; M Jullien; E May; J C Bourdon
Journal:  Oncogene       Date:  2000-11-30       Impact factor: 9.867

9.  Analysis of p53 expression in human tumours: an antibody raised against human p53 expressed in Escherichia coli.

Authors:  C A Midgley; C J Fisher; J Bártek; B Vojtĕsek; D Lane; D M Barnes
Journal:  J Cell Sci       Date:  1992-01       Impact factor: 5.285

10.  Wild-type alternatively spliced p53: binding to DNA and interaction with the major p53 protein in vitro and in cells.

Authors:  Y Wu; Y Liu; L Lee; Z Miner; M Kulesz-Martin
Journal:  EMBO J       Date:  1994-10-17       Impact factor: 11.598

View more
  325 in total

Review 1.  The role of p53 gene family in reproduction.

Authors:  Wenwei Hu
Journal:  Cold Spring Harb Perspect Biol       Date:  2009-10-28       Impact factor: 10.005

2.  Mdm2 and aurora kinase a inhibitors synergize to block melanoma growth by driving apoptosis and immune clearance of tumor cells.

Authors:  Anna E Vilgelm; Jeff S Pawlikowski; Yan Liu; Oriana E Hawkins; Tyler A Davis; Jessica Smith; Kevin P Weller; Linda W Horton; Colt M McClain; Gregory D Ayers; David C Turner; David C Essaka; Clinton F Stewart; Jeffrey A Sosman; Mark C Kelley; Jeffrey A Ecsedy; Jeffrey N Johnston; Ann Richmond
Journal:  Cancer Res       Date:  2014-11-14       Impact factor: 12.701

3.  Aurora A mediates cross-talk between N- and C-terminal post-translational modifications of p53.

Authors:  Lorna Jane Warnock; Sally Anne Raines; Jo Milner
Journal:  Cancer Biol Ther       Date:  2011-12-15       Impact factor: 4.742

4.  p53 basic C terminus regulates p53 functions through DNA binding modulation of subset of target genes.

Authors:  Pierre-Jacques Hamard; Dana J Lukin; James J Manfredi
Journal:  J Biol Chem       Date:  2012-04-18       Impact factor: 5.157

5.  Differentiated embryo-chondrocyte expressed gene 1 regulates p53-dependent cell survival versus cell death through macrophage inhibitory cytokine-1.

Authors:  Yingjuan Qian; Yong-Sam Jung; Xinbin Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-21       Impact factor: 11.205

6.  Splicing of mouse p53 pre-mRNA does not always follow the "first come, first served" principle and may be influenced by cisplatin treatment and serum starvation.

Authors:  Min Yang; Jack Wu; Si-Hung Wu; An-Ding Bi; D Joshua Liao
Journal:  Mol Biol Rep       Date:  2012-06-28       Impact factor: 2.316

7.  A genome-wide aberrant RNA splicing in patients with acute myeloid leukemia identifies novel potential disease markers and therapeutic targets.

Authors:  Sophia Adamia; Benjamin Haibe-Kains; Patrick M Pilarski; Michal Bar-Natan; Samuel Pevzner; Herve Avet-Loiseau; Laurence Lode; Sigitas Verselis; Edward A Fox; John Burke; Ilene Galinsky; Ibiayi Dagogo-Jack; Martha Wadleigh; David P Steensma; Gabriela Motyckova; Daniel J Deangelo; John Quackenbush; Richard Stone; James D Griffin
Journal:  Clin Cancer Res       Date:  2013-11-27       Impact factor: 12.531

8.  The first two confirmed sub-Saharan African families with germline TP53 mutations causing Li-Fraumeni syndrome.

Authors:  Shelley Macaulay; Quintin Clive Goodyear; Mia Kruger; Wenlong Chen; Fahmida Essop; Amanda Krause
Journal:  Fam Cancer       Date:  2018-10       Impact factor: 2.375

Review 9.  The Tail That Wags the Dog: How the Disordered C-Terminal Domain Controls the Transcriptional Activities of the p53 Tumor-Suppressor Protein.

Authors:  Oleg Laptenko; David R Tong; James Manfredi; Carol Prives
Journal:  Trends Biochem Sci       Date:  2016-09-23       Impact factor: 13.807

10.  Altered mammary gland development in the p53+/m mouse, a model of accelerated aging.

Authors:  Catherine E Gatza; Melissa Dumble; Frances Kittrell; David G Edwards; Robert K Dearth; Adrian V Lee; Jianming Xu; Daniel Medina; Lawrence A Donehower
Journal:  Dev Biol       Date:  2007-10-12       Impact factor: 3.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.